Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates

Summary

Factor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To date, no systematic information is available about the substrate specificity of FSAP. Applying phage display and positional scanning substrate combinatorial library (PS-SCL) approaches we have characterised the specificity of FSAP towards small peptides. Results were evaluated in the context of known protein substrates as well as molecular modelling of the peptides in the active site of FSAP. The representative FSAP-cleaved sequence obtained from the phage display method was Val-Leu-Lys-Arg-Ser (P4-P1’). The sequence X-Lys/Arg-Nle-Lys/Arg (P4-P1) was derived from the PS-SCL method. These results show a predilection for cleavage at a cluster of basic amino acids on the nonprime side. Quenched fluorescent substrate (Ala-Lys-Nle-Arg-AMC) (amino methyl coumarin) and (Ala-Leu-Lys-Arg-AMC) had a higher selectivity for FSAP compared to other proteases from the hemostasis system. These substrates could be used to measure FSAP activity in a complex biological system such as plasma. In histonetreated plasma there was a specific activation of pro-FSAP as validated by the use of an FSAP inhibitory antibody, corn trypsin inhibitor to inhibit Factor XIIa and hirudin to inhibit thrombin, which may account for some of the haemostasis-related effects of histones. These results will aid the development of further selective FSAP activity probes as well as specific inhibitors that will help to increase the understanding of the functions of FSAP in vivo.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Serine protease - phage display - peptide substrates - library

• References

• 1 Leiting S, Seidl S, Martinez-Palacian A. et al. Transforming Growth Factor-beta (TGF-beta) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes. J Biol Chem 2016; 291: 21020-21028.
• 2 Yamamichi S, Fujiwara Y, Kikuchi T. et al. Extracellular histone induces plasma hyaluronan-binding protein (factor VII activating protease) activation in vivo. Biochem Biophys Res Commun 2011; 409: 483-488.
• 3 Hunfeld A, Etscheid M, Konig H. et al. Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors. FEBS Lett 1999; 456: 290-294.
• 4 Choi-Miura NH, Saito K, Takahashi K. et al. Regulation mechanism of the serine protease activity of plasma hyaluronan binding protein. Biol Pharm Bull 2001; 24: 221-225.
• 5 Romisch J, Vermohlen S, Feussner A. et al. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999; 29: 292-299.
• 6 Etscheid M, Hunfeld A, Konig H. et al. Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol Chem 2000; 381: 1223-1231.
• 7 Wygrecka M, Morty RE, Markart P. et al. Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. J Biol Chem 2007; 282: 21671-21682.
• 8 Muhl L, Nykjaer A, Wygrecka M. et al. Inhibition of PDGF-BB by Factor VII-activating protease (FSAP) is neutralized by protease nexin-1, and the FSAP-inhibitor complexes are internalized via LRP. Biochem J 2007; 404: 191-196.
• 9 Roemisch J, Feussner A, Nerlich C. et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinolysis 2002; 13: 433-441.
• 10 Etscheid M, Muhl L, Pons D. et al. The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity. Thrombosis Res 2012; 130: 935-941.
• 11 Willeit J, Kiechl S, Weimer T. et al. Marburg I polymorphism of factor VII--activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003; 107: 667-670.
• 12 Wasmuth HE, Tag CG, Van de Leur E. et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology 2009; 49: 775-780.
• 13 Trompet S, Pons D, Kanse SM. et al. Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality. Stroke Res Treat 2011; 2011: 424759.
• 14 Ahmad-Nejad P, Dempfle CE, Weiss C. et al. The G534E–polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events. Thrombosis Res 2012; 130: 441-444.
• 15 Reiner AP, Lange LA, Smith NL. et al. Common haemos tasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study. J Thromb Haemost 2009; 07: 1499-1505.
• 16 van Minkelen R, de Visser MC, Vos HL. et al. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005; 105: 4898.
• 17 Ngeow J, Eng C. HABP2 in Familial Non-medullary Thyroid Cancer: Will the Real Mutation Please Stand Up?. J Natl Cancer Inst 2016; 108.
• 18 Gara SK, Jia L, Merino MJ. et al. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med 2015; 373: 448-455.
• 19 Borkham-Kamphorst E, Zimmermann HW, Gassler N. et al. Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. J Hepatol 2013; 58: 104-111.
• 20 Joshi AU, Orset C, Engelhardt B. et al. Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice. Eur J Neurosci 2015; 41: 965-975.
• 21 Daniel JM, Reichel CA, Schmidt-Woell T. et al. Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation. J Thromb Haemost 2016; 14: 2058-2067.
• 22 Subramaniam S, Thielmann I, Morowski M. et al. Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP). Thromb Haemost 2015; 113: 870-880.
• 23 Loset GA, Bogen B, Sandlie I. Expanding the versatility of phage display I: efficient display of peptide-tags on protein VII of the filamentous phage. PloS one 2011; 06: e14702.
• 24 Scholle MD, Kriplani U, Pabon A. et al. Mapping protease substrates by using a biotinylated phage substrate library. Chembiochem 2006; 07: 834-838.
• 25 Katoh K, Toh H. Parallelisation of the MAFFT multiple sequence alignment program. Bioinformatics 2010; 26: 1899-1900.
• 26 Colaert N, Helsens K, Martens L. et al. Improved visualisation of protein consensus sequences by iceLogo. Nature Methods 2009; 06: 786-787.
• 27 Schneider EL, Craik CS. Positional scanning synthetic combinatorial libraries for substrate profiling. Methods Mol Biol 2009; 539: 59-78.
• 28 Biasini M, Bienert S, Waterhouse A. et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014; 42: W252-258.
• 29 Pettersen EF, Goddard TD, Huang CC. et al. UCSF Chimera--a visualisation system for exploratory research and analysis. J Comp Chem 2004; 25: 1605-1612.
• 30 Wu S, Zhang Y. ANGLOR: a composite machine-learning algorithm for protein backbone torsion angle prediction. PloS one 2008; 03: e3400.
• 31 Emsley P, Lohkamp B, Scott WG. et al. Features and development of Coot. Acta Crystallographica D 2010; 66: 486-501.
• 32 London N, Raveh B, Cohen E. et al. Rosetta FlexPepDock web server--high resolution modeling of peptide-protein interactions. Nucleic Acids Res 2011; 39: W249-253.
• 33 Shibamiya A, Muhl L, Tannert-Otto S. et al. Nucleic acids potentiate Factor VII-activating protease (FSAP)-mediated cleavage of platelet-derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation. Biochem J 2007; 404: 45-50.
• 34 Etscheid M, Beer N, Fink E. et al. The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin. Biol Chem 2002; 383: 1633-1643.
• 35 Kanse SM, Declerck PJ, Ruf W. et al. Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. Arterioscl Thromb Vasc Biol 2012; 32: 427-433.
• 36 Kanse SM, Gallenmueller A, Zeerleder S. et al. Factor VII-activating protease is activated in multiple trauma patients and generates anaphylatoxin C5a. J Immunol 2012; 188: 2858-2865.
• 37 Choi-Miura NH, Yoda M, Saito K. et al. Identification of the substrates for plasma hyaluronan binding protein. Biol Pharm Bull 2001; 24: 140-143.
• 38 Altincicek B, Shibamiya A, Trusheim H. et al. A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. Biochem J 2006; 394: 687-692.
• 39 Renatus M, Engh RA, Stubbs MT. et al. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J 1997; 16: 4797-4805.
• 40 Stephan F, Hazelzet JA, Bulder I. et al. Activation of factor VII-activating protease in human inflammation: a sensor for cell death. Crit Care 2011; 15: R110.
• 41 Gosalia DN, Salisbury CM, Maly DJ. et al. Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays. Proteomics 2005; 05: 1292-1298.
• 42 Muhl L, Galuska SP, Oorni K. et al. High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease. FEBS J 2009; 276: 4828-4839.
• 43 Angliker H. Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J Med Chem 1995; 38: 4014-4018.